Disitamab Vedotin

6 trials 5 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

5 Recruiting

0 Completed trials

2 Sponsors

14 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 3 Phase I/II: 2

Oversight events:

1 serious breach 2 temporary halts 1 corrective measure across 1 trial

View oversight register →

Indications tested

Ovarian cancer 1 Endometrial cancer 1 HER2 positive breast cancer 1 Oesophageal adenocarcinoma 1 HER2 low breast cancer 1 Head and neck cancer 1 Non-small cell lung cancer 1 Gastric cancer 1 HER2 ultralow breast cancer 1

Sponsors using this IMP

Seagen Inc. 5 Pfizer Inc. 1

All trials

6 total

A Study of Disitamab Vedotin Alone and with Pembrolizumab in Urothelial Cancer That Expresses HER2 Not authorised

2022-500030-28-00 Phase II 4 countries Seagen Inc.
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting

2023-504445-31-00 Phase II 4 countries Seagen Inc.
A Study of Disitamab Vedotin with Other Anticancer Drugs in Solid Tumors Recruiting

2023-507555-29-00 Phase I/II 4 countries Seagen Inc.
Disitamab Vedotin with Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 Recruiting

2022-501105-12-00 Phase III 13 countries Seagen Inc.
A Study of Disitamab Vedotin Alone or with Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting

2022-500030-28-01 Phase II 4 countries Seagen Inc.
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting

2025-521003-52-00 Phase I/II 3 countries Pfizer Inc.

Showing 1–6 of 6 trials

← All drugs A–Z